Product Information
AMITRIPTYLINE HCL 25 MG TAB is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $0.0522 per EA under NDC 70710122601. Its NADAC has been published 418 times since Oct 3, 2018.
FDA first approved this application on Oct 6, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25 mg/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
70710122601
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AMITRIPTYLINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA210086FDA Approved
10/6/2017
TE Code
AB
On Market Since
12/26/2017
Pharmacological Classes
Price Statistics
The NADAC for AMITRIPTYLINE HCL 25 MG TAB has been published 418 times since Oct 3, 2018, and over the history we have for it it has declined 67.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0522 per EA |
|---|---|
| All-time high | $0.1638 (Dec 12, 2018) |
| All-time low | $0.0411 (Nov 20, 2024) |
| 52-week high | $0.0566 |
| 52-week low | $0.0509 |
| Median price | $0.0664 |
| Average price | $0.0821 |
| Largest weekly change | -27.3% (Nov 20, 2024) |
| Weeks tracked | 418 |
| Tracking since | Oct 3, 2018 |
Generic Alternatives
The matcher finds 12 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Zydus Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Amitriptyline Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Tricyclic Antidepressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AMITRIPTYLINE HCL 25 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for AMITRIPTYLINE HCL 25 MG TAB, manufactured by Zydus Pharmaceuticals (USA) Inc., is $0.0522 per EA (NDC 70710122601), effective Sep 30, 2026.
How has the price of AMITRIPTYLINE HCL 25 MG TAB changed over time?
Over the history we have for it, the NADAC for AMITRIPTYLINE HCL 25 MG TAB has declined 67.6%. It has been tracked across 418 weekly CMS publications since Oct 3, 2018.
What are the highest and lowest recorded NADAC prices for AMITRIPTYLINE HCL 25 MG TAB?
Since Oct 3, 2018, the NADAC for AMITRIPTYLINE HCL 25 MG TAB has ranged from a low of $0.0411 (Nov 20, 2024) to a high of $0.1638 (Dec 12, 2018), with a median of $0.0664 per EA.
Are there cheaper alternatives to AMITRIPTYLINE HCL 25 MG TAB?
12 manufacturers publish a NADAC-priced product with the same active ingredient and strength as AMITRIPTYLINE HCL 25 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures AMITRIPTYLINE HCL 25 MG TAB?
AMITRIPTYLINE HCL 25 MG TAB (NDC 70710122601) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.